| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $3.5M | — | +112.2% |
| SG&A Expense | $1.7M | — | +10.1% |
| Operating Income | -$5.2M | — | -62.2% |
| Net Income | -$3.9M | — | -48.3% |
| EPS (Basic) | -$0.46 | — | -21.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $52.5M | -15.0% | +32.3% |
| Current Assets | $137.7M | -1.9% | +150.1% |
| Total Assets | $138.0M | -1.9% | +150.5% |
| Current Liabilities | $2.5M | -10.1% | — |
| Total Liabilities | $2.6M | -10.4% | +73.6% |
| Stockholders' Equity | $135.4M | -1.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.5M | — | +38.7% |
| Investing Cash Flow | -$5.6M | — | -1613.7% |
| Financing Cash Flow | -$200K | — | -73.1% |
| +152.6% |